Succeeder(SH:688338) Sou Hu Cai Jing·2026-01-31 19:26Core Viewpoint - The company Sikehde (688338) is experiencing a decline in financial performance, primarily due to the impact of medical insurance cost control policies on the in vitro diagnostic industry, leading to reduced market demand and a significant drop in reagent revenue [1][3]. Financial Performance Summary - As of January 30, 2026, Sikehde's stock closed at 29.04 yuan, up 0.17% from the previous week, with a market capitalization of 3.082 billion yuan [1]. - The company is set to release its 2025 annual report, with a preliminary report indicating a net profit attributable to shareholders of 87.14 million yuan, a year-on-year decrease of 22.88% [1][3]. - Total operating revenue for 2025 is reported at 263.67 million yuan, reflecting a year-on-year decline of 13.80% [1][3]. - The net profit after deducting non-recurring gains and losses decreased by 26.31% year-on-year [1][3]. - Total assets increased by 0.99% compared to the beginning of the period, while equity attributable to shareholders grew by 2.50% [1][3].